Laure-Anne Teuwen
Overview
Explore the profile of Laure-Anne Teuwen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
2464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boen H, Pype L, Papadimitriou K, Altintas S, Teuwen L, Anguille S, et al.
Cardiooncology
. 2025 Mar;
11(1):27.
PMID: 40087712
Background: SERPINA3 recently emerged as potential prognostic biomarker in heart failure. In a population of cancer survivors with cancer therapy-related cardiac dysfunction (CTRCD) circulating SERPINA3 was elevated compared to age-matched...
2.
Van den Bosch L, Vanclooster P, Van Offenwert J, Teuwen L, Franssen C
Eur Heart J Case Rep
. 2025 Mar;
9(3):ytaf058.
PMID: 40061108
Background: Disseminated infection is a severe condition in immunocompromised patients. Mortality secondary to cardiac infection remains high. Case Summary: We present a case of a 45-year-old female breast cancer patient...
3.
Seghers S, Mando P, Eid M, Tan C, Jayraj A, Jatwani K, et al.
JCO Oncol Pract
. 2025 Feb;
:OP2400739.
PMID: 40014833
Purpose: The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the ASCO Value Framework (ASCO-VF) are tools designed to assess the value of anticancer therapies. International conferences...
4.
Tjalma W, Teuwen L, Altintas S, Papadimitriou K
Breast
. 2025 Jan;
:103885.
PMID: 39890556
The standard of care for HER2-positive and hormone receptor-positive breast cancer patients who receive neoadjuvant chemotherapy (NACT) combined with trastuzumab, with or without pertuzumab, is to continue with adjuvant T-DM1...
5.
El Bairi K, Trapani D, Teuwen L, Rodrigues B, Mutebi M
BJC Rep
. 2024 Nov;
2(1):11.
PMID: 39516262
No abstract available.
6.
Plummer R, Greystoke A, Naylor G, Sarker D, Anam A, Prenen H, et al.
J Hepatocell Carcinoma
. 2024 Oct;
11:2033-2047.
PMID: 39469286
Purpose: To evaluate safety, preliminary efficacy, pharmacokinetics, and pharmacodynamics, of fostroxacitabine bralpamide (fostrox, MIV-818), a novel oral troxacitabine nucleotide prodrug designed to direct exposure to the liver, while minimizing systemic...
7.
Teuwen L, Young J, Alessy S, Ozdemir B, Martina D, Folorunso S, et al.
JCO Glob Oncol
. 2024 Oct;
10():e2400238.
PMID: 39361907
Purpose: Multiple disparities have been recognized in the area of location, gender, and funding for leadership in oncology clinical trials. Understanding their intersectionality is crucial to be able to formulate...
8.
Teuwen L, Ahmad Z, Segelov E
JCO Glob Oncol
. 2024 Aug;
10:e2400136.
PMID: 39116364
Time to update abstract submission categories to promote dissemination of global oncology research.
9.
El Bairi K, Najem S, Chowdhury A, Omar A, Abdihamid O, Teuwen L, et al.
JCO Glob Oncol
. 2024 Jun;
10:e2400167.
PMID: 38822759
Purpose: Conflicts of interest (COIs) between oncologists and industry might considerably influence how the presentation of the research results is delivered, ultimately affecting clinical decisions and policy-making. Although there are...
10.
Geerinckx B, Teuwen L, Foo T, Vandamme T, Smith A, Peeters M, et al.
Expert Rev Anticancer Ther
. 2023 Oct;
23(12):1237-1249.
PMID: 37842857
Introduction: Prognosis of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) remains disappointing with a 5-year overall survival of only 3-5%. Compared to other cancers, the evolution in standard therapeutic options...